Insider Transactions in Q1 2021 at Theravance Biopharma, Inc. (TBPH)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2021
|
Philip D Worboys SVP, RESEARCH & TRANSL SCIENCE |
SELL
Open market or private sale
|
Direct |
8,829
-2.5%
|
$176,580
$20.0 P/Share
|
|
Feb 20
2021
|
Ann Brady PRESIDENT, TBIL |
SELL
Payment of exercise price or tax liability
|
Direct |
10,092
-7.3%
|
$181,656
$18.79 P/Share
|
|
Feb 20
2021
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
6,597
-3.5%
|
$118,746
$18.79 P/Share
|
|
Feb 20
2021
|
Brett K Haumann Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,672
-12.82%
|
$642,096
$18.79 P/Share
|
|
Feb 20
2021
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,984
-2.11%
|
$71,712
$18.79 P/Share
|
|
Feb 20
2021
|
Frank Pasqualone SVP, CHIEF BUSINESS OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
26,961
-5.78%
|
$485,298
$18.79 P/Share
|
|
Feb 20
2021
|
Kenneth R Pitzer SVP, PROD STRAT & COMM PLNG |
SELL
Payment of exercise price or tax liability
|
Direct |
31,931
-7.98%
|
$574,758
$18.79 P/Share
|
|
Feb 20
2021
|
Vijay Sabesan SVP, TECHNICAL OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
8,343
-3.23%
|
$150,174
$18.79 P/Share
|
|
Feb 20
2021
|
Bradford J Shafer EVP, Gen. Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
31,869
-10.06%
|
$573,642
$18.79 P/Share
|
|
Feb 20
2021
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
110,348
-7.64%
|
$1,986,264
$18.79 P/Share
|
|
Feb 20
2021
|
Philip D Worboys SVP, RESEARCH & TRANSL SCIENCE |
SELL
Payment of exercise price or tax liability
|
Direct |
31,887
-8.3%
|
$573,966
$18.79 P/Share
|
|
Feb 08
2021
|
Ann Brady PRESIDENT, TBIL |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+22.44%
|
-
|
|
Feb 08
2021
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+25.62%
|
-
|
|
Feb 08
2021
|
Frank Pasqualone SVP, CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+12.23%
|
-
|
|
Feb 08
2021
|
Kenneth R Pitzer SVP, PROD STRAT & COMM PLNG |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+13.97%
|
-
|
|
Feb 08
2021
|
Vijay Sabesan SVP, TECHNICAL OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+20.12%
|
-
|
|
Feb 08
2021
|
Bradford J Shafer EVP, Gen. Counsel, Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+17.02%
|
-
|
|
Feb 08
2021
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
170,000
+10.53%
|
-
|
|
Feb 08
2021
|
Philip D Worboys SVP, RESEARCH & TRANSL SCIENCE |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+14.46%
|
-
|
|
Feb 08
2021
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+25.62%
|
-
|